T025 is an orally active and highly potent inhibitor of Cdc2-like kinase (CLKs), demonstrating Kd values of 4.8, 0.096, 6.5, 0.61, 0.074, 1.5, and 32 nM for CLK1, CLK2, CLK3, CLK4, DYRK1A, DYRK1B, and DYRK2, respectively. This compound induces caspase-3/7-mediated cell apoptosis and reduces CLK-dependent phosphorylation. T025 exhibits anti-proliferative activities in both hematological and solid cancer cell lines with IC50 values ranging from 30-300 nM, making it primarily useful for MYC-driven disease research.
- Orally active and highly potent inhibitor of Cdc2-like kinase (CLKs)
- Induces caspase-3/7-mediated cell apoptosis
- Reduces CLK-dependent phosphorylation
- Exerts anti-proliferative activities in both hematological and solid cancer cell lines
- Anti-tumor efficiency, mainly for MYC-driven disease research